Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion

American Heart Journal

Volumn 167, Issue 5, 2014, Pages 646-652

  Ezekowitz, Michael D ^a,b   Cappato, Riccardo ^c,j   Klein, Allan L ^d   Camm, A John ^e   Ma, Chang Sheng ^f   Le Heuzey, Jean Yves ^g   Talajic, Mario ^h   Scanavacca, Maurício I ⁱ   Vardas, Panos E ^j   Kirchhof, Paulus ^k,l   Hohnloser, Stefan H ^m   Hemmrich, Melanie ⁿ   Lanius, Vivian ^o   Meng, Isabelle Ling ^p   Wildgoose, Peter ^q   Van Eickels, Martin ^p  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d LERNER RESEARCH INSTITUTE   (United States)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m GOETHE UNIVERSITY   (Germany)

ⁿ BAYER AG   (Germany)

^o Bayer Schering Pharma   (Germany)

^p Bayer Healthcare   (Germany)

^q JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; FLUINDIONE; PHENPROCOUMON; RIVAROXABAN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ELECTIVE CARDIOVERSION; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMODYNAMICS; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; EMBOLISM; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORPHOLINES; PROSPECTIVE STUDIES; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K;

EID: 84899547365     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.12.024     Document Type: Article

References (19)

1. W.B. Kannel, R.D. Abbott, and D.D. Savage et al. Coronary heart disease and atrial fibrillation: the Framingham study Am Heart J 106 1983 389 396
2. A.S. Go, E.M. Hylek, and K.A. Phillips et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
3. S. Stewart, C.L. Hart, and D.J. Hole et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Heart 86 2001 516 521
4. E.N. Prystowsky, D.W. Benson Jr., and V. Fuster et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation 93 1996 1262 1277
5. A.J. Camm, P. Kirchhof, and G.Y.H. Lip et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
6. V. Fuster, L.E. Rydén, and D.S. Cannom et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 e269 e367
7. J.J. You, D.E. Singer, and P.A. Howard et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e531S e575S
8. A.L. Klein, R.A. Grimm, and R.D. Murray et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411 1420
9. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
10. C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
12. R. Nagarakanti, M.D. Ezekowitz, and J. Oldgren et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
13. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
14. G. Flaker, R.D. Lopes, and S.M. Al-Khatib et al. Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: insights from the ARISTOTLE trial J Am Coll Cardiol 2013 [ePub]
15. Bayer Pharma AG Xarelto (rivaroxaban) summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000944/WC500057108.pdf 2013 Last accessed August 13, 2013
16. Boehringer Ingelheim International GmbH Pradaxa (dabigatran etexilate) summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000829/WC500041059.pdf 2013 Last accessed November 18, 2013
17. Bristol-Myers Squibb, and Pfizer EEIG Eliquis (apixaban) summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002148/WC500107728.pdf 2013 Last accessed November 18, 2013
18. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
19. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41